Encephalitis Caused by Epstein‐Barr Virus in a Renal Transplant Recipient

Basal ganglia and brainstem encephalitis, optic neuritis, and radiculomyelitis in Epstein–Barr virus infection

“…There is only one report each of EBV encephalitis with bilateral basal ganglia lesions, 13 bilateral thalamic and basal ganglia lesions, 14 brainstem lesions, 15 and unilateral thalamic lesion with multiple cerebral and brainstem lesions. 16 Thus, our patient is the first report of EBV encephalitis with bilateral basal ganglia and brainstem lesions.…”

Thalamic involvement of Epstein-Barr virus encephalitis demonstrated by MRI

“…EBV is reported to cause bilateral basal ganglia lesions [2] and brainstem lesions [1], and recently, a unilateral thalamic lesion with multiple cerebral and brainstem lesions was reported in a renal transplant recipient with EBV encephalitis [3]. However, to our knowledge, there is no report of EBV encephalitis with lesions involving the thalamus bilaterally, like those of Japanese encephalitis.…”

Epstein–Barr virus encephalitis in a renal transplant recipient manifesting as hemorrhagic, ring‐enhancing mass lesions

“…EBV accounts for between 1% and 6% of cases of encephalitis, and has classically been described in children and young adults as a complication of infectious mononucleosis . EBV encephalitis has only occasionally been described in immunocompromised patients including those with human immunodeficiency virus (HIV) , corticosteroid use , solid organ transplantation (almost exclusively renal transplantation) , and bone marrow transplantation . In these patients, EBV encephalitis is usually the result of reactivation rather than primary infection .…”

“…Epstein–Barr virus (EBV) encephalitis has classically been described in children and young adults as a complication of infectious mononucleosis , and has only occasionally been described in immunocompromised patients . The diagnosis is challenging given the lack of specificity of cerebrospinal fluid (CSF) EBV polymerase chain reaction (PCR) in immunocompromised patients.…”